US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of MM120 orally disintegrating tablets (MM120 ODT) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback